Kiadis Pharma
Zernikepark 6-8
Groningen
9747 AN
Tel: 31-0-50-547-42-70
Fax: 31-0-50-547-42-71
Website: http://www.kiadis.com/
Email: info@kiadis.com
78 articles about Kiadis Pharma
-
Notice of Annual General Meeting of Shareholders - May 13, 2021
5/13/2021
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V., a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders will be held at 15:00 CEST on 28 June 2021.
-
Kiadis has three compounds in the clinic: K-NK002 in Phase II for HSCT in blood cancer; K-NK003 for relapsed or refractory acute myeloid leukemia (AML); K-NK-ID101 for COVID-19.
-
Kiadis Pharma, based in Amsterdam, The Netherlands, licensed a previously undisclosed K-NK0004 program to Paris-based Sanofi.
-
Kiadis Pharma announces FDA clearance of clinical study by The Ohio State University in R/R AML with off-the-shelf NK cells from universal donors
2/26/2020
Kiadis Pharma N.V. announced the launch of a first-in-human clinical trial in patients with relapsed/refractory acute myeloid leukemia with off-the-shelf Natural Killer cells manufactured using Kiadis’ FC21 mbIL21 feeder cells and proprietary universal donor platform.
-
Kiadis Pharma to present at the 2019 Piper Jaffray 31st Annual Healthcare Conference
11/25/2019
Kiadis Pharma N.V., a clinical stage biopharmaceutical company, announces that Kiadis will participate in the 2019 Piper Jaffray 31st Annual Healthcare Conference.
-
The company will discontinue development of its lead T-cell asset, ATIR101, halt its ongoing Phase III trial and lay off half its staff.
-
Kiadis Pharma announces formation of renowned Scientific Advisory Board
10/22/2019
Kiadis Pharma N.V. announces the formation of its Scientific Advisory Board comprised of world-leading experts in the field of oncology and cell therapy.
-
Kiadis to Acquire CytoSen Therapeutics, Inc.
4/17/2019
Transaction creates leader in cell-based cancer immunotherapy, with complementary T-cell and NK-cell platforms focused initially on hematopoietic stem cell transplants (HSCT)
-
The combination of the two companies will create a leader in cell-based cancer immunotherapy, Kiadis said. It also further expands Kiadis’ toehold in the United States.
-
Kiadis Pharma strengthens core team with three senior appointments
11/8/2018
Kiadis Pharma N.V. today announces that it has appointed three new senior team members to further strengthen the Company as it transitions into commercial stage.
-
Kiadis Pharma provides regulatory and clinical update on ATIR101
10/12/2018
Potential CHMP opinion moved from Q4 2018 into H1 2019
-
Kiadis Pharma: Cellular Immunotherapy Presentation At 4th Cell And Gene Therapy Conference Review Of Phase I And II ATIR101 Data
9/19/2017
-
Kiadis Pharma Obtains Up To €15 Million Debt Financing From Kreos Capital
8/17/2017
-
Kiadis Pharma To Present Information On The Design Of Its Phase III Trial With ATIR101 And Phase I/II Trial With ATIR201 At 43rd Annual Meeting Of The European Society For Blood And Marrow Transplantation
3/16/2017
-
Kiadis Pharma To Present Atir10 Phase II Trial Data In Late Breaking Abstract At The International Society For Cellular Therapy (ISCT) 2017 Annual Meeting
3/13/2017
-
Kiadis Pharma Issues Clinical And Regulatory Progress Update On ATIR101 And ATIR201
2/6/2017
-
Kiadis Pharma Provides Update On Second Dose Trial (CR-AIR-008) With ATIR101
12/21/2016
-
Kiadis Pharma Announces Initiation Of A Phase I/II Clinical Trial With ATIR201 For Thalassemia
12/15/2016
-
Kiadis Pharma: Planned Management Team Changes
12/8/2016
-
Kiadis Pharma Presents Positive 1-Year Follow-Up Data Of Its Pivotal Phase II Trial With ATIR101
12/6/2016